Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-11-19 00:39Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration [2][3] Drug Information and Research Status - The drug is a chemical medication intended for the treatment of chronic constipation (excluding constipation caused by organic diseases) [3] - As of October 2025, the cumulative R&D investment for the Compound Polyethylene Glycol Electrolyte Powder series, including this drug, is approximately RMB 6.21 million (unaudited) [3] - According to the latest IQVIA CHPA data, the sales revenue for Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 873 million in 2024 [3]